Non-adenosine nucleoside inosine, guanosine and uridine as promising antiepileptic drugs: A summary of current literature

Mini-Reviews in Medicinal Chemistry

Volumn 14, Issue 13, 2014, Pages 1033-1042

  Kovács, Zsolt ^a   Kékesi, Katalin A ^b   Juhász, Gábor ^b   Barna, János ^c   Héja, László ^d   Lakatos, Renáta ^a   Dobolyi, Árpád ^c,d  

^a UNIVERSITY OF WEST HUNGARY   (Hungary)

^b EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Epilepsy; Guanosine; Inosine; Uridine

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 7 METHYLINOSINE; ACICLOVIR; ADENOSINE RECEPTOR; ANTICONVULSIVE AGENT; DEOXYINOSINE; GUANOSINE; INO 2002; INOSINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N3 ALPHA HYDROXY BETA PHENACYLURIDINE; N3 PHENACYLURIDINE; NUCLEOSIDE TRANSPORTER; UNCLASSIFIED DRUG; URIDINE; ADENOSINE; NUCLEOSIDE;

ANTICONVULSANT ACTIVITY; ARTICLE; DRUG MECHANISM; EPILEPSY; EVOKED RESPONSE; EXCITATION AND STIMULATION; GABAERGIC SYSTEM; HUMAN; ION TRANSPORT; MEMBRANE POTENTIAL; NEUROTRANSMISSION; NONHUMAN; NUCLEOSIDE TRANSPORT; NUCLEOTIDE METABOLISM; SEIZURE; SIGNAL TRANSDUCTION; SYNAPSE; ANIMAL; CHEMISTRY;

ADENOSINE; ANIMALS; ANTICONVULSANTS; GUANOSINE; HUMANS; INOSINE; NUCLEOSIDES; URIDINE;

EID: 84921835796     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557514666141107120226     Document Type: Article

References (143)

1. Ipata, P.L.; Camici, M.; Micheli, V.; Tozzi, M.G. Metabolic network of nucleosides in the brain. Curr. Top. Med. Chem., 2011, 11(8), 909-922.
2. Kovács, Z.; Juhász, G.; Palkovits, M.; Dobolyi, A.; Kékesi, K.A. Area, age and gender dependence of the nucleoside system in the brain: a review of current literature. Curr. Top. Med. Chem., 2011, 11(8), 1012-1033.
3. Burnstock, G.; Fredholm, B.B.; Verkhratsky, A. Adenosine and ATP receptors in the brain. Curr. Top. Med. Chem., 2011, 11(8), 973-1011.
4. Cunha, R.A. Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors. Neurochem. Int., 2001, 38(2), 107-125.
5. Inoue, K.; Kato, F.; Tsuda, M. The modulation of synaptic transmission by the glial purinergic system. Open Neurosi. J., 2010, 4, 84-92.
6. Ipata, P.L.; Balestri, F.; Tozzi, M.G.; Camici, M. Brain nucleoside recycling. Metabolomics, 2012, DOI 10.1007/s11306-012-0457-x.
7. Schmidt, A.P.; Lara, D.R.; Souza, D.O. Proposal of a guaninebased purinergic system in the mammalian central nervous system. Pharmacol. Ther., 2007, 116(3), 401-416.
8. Zimmermann, H. Biochemistry, localization and functional roles of ecto-nucleotidases in the nervous system. Prog. Neurobiol., 1996, 49(6), 589-618.
9. Ciccarelli, R.; Ballerini, P.; Sabatino, G.; Rathbone, M.P.; D'Onofrio, M.; Caciagli, F.; Di Iorio, P. Involvement of astrocytes in purine-mediated reparative processes in the brain. Int. J. Dev. Neurosci., 2001, 19(4), 395-414.
10. Dias, R.B.; Rombo, D.M.; Ribeiro, J.A.; Henley, J.M.; Sebastião, A.M. Adenosine: setting the stage for plasticity. Trends Neurosci., 2013, 36(4), 248-257.
11. Fredholm, B.B.; Vernet, L. Release of 3H-nucleosides from 3Hadenine labelled hypothalamic synaptosomes. Acta Physiol. Scand., 1979, 106(2), 97-107.
12. Lovatt, D.; Xu, Q.; Liu, W.; Takano, T.; Smith, N.A.; Schnermann, J.; Tieu, K.; Nedergaard, M. Neuronal adenosine release, and not astrocytic ATP release, mediates feedback inhibition of excitatory activity. Proc. Natl. Acad. Sci. U.S.A., 2012, 109(16), 6265-6270.
13. Parkinson, F.E.; Damaraju, V.L.; Graham, K.; Yao, S.Y.M.; Baldwin, S.A.; Cass, C.E.; Young, J.D. Molecular biology of nucleoside transporters and their distributions and functions in the brain. Curr. Top. Med. Chem., 2011, 11(8), 948-972.
14. Song, W.; Wu, C.F.; Liu, P.; Xiang, R.W.; Wang, F.; Dong, Y.X.; Yang, J.Y. Characterization of basal and morphine-induced uridine release in the striatum: an in vivo microdialysis study in mice. Neurochem. Res., 2013, 38(1), 153-161.
15. Kimura, T.; Ho, I.K.; Yamamoto, I. Uridine receptor: discovery and its involvement in sleep mechanism. Sleep, 2001, 24(3), 251- 260.
16. Kimura, T.; Miki, M.; Ikeda, M.; Yonemoto, S.; Watanabe, K.; Kondo, S.; Ho, I.K.; Yamamoto, I. Possible existence of a novel receptor for uridine analogues in the central nervous system using two isomers, N3-(S)-(+)- and N3-(R)-(-)-alpha-hydroxy-betaphenethyluridines. Biol. Pharm. Bull., 2001, 24(6), 729-731.
17. Kovács, I.; Lasztóczi, B.; Szárics, É.; Héja, L.; Sági, G.; Kardos, J. Characterisation of an uridine-specific binding site in rat cerebrocortical homogenates. Neurochem. Int., 2003, 43(2), 101- 112.
18. Volpini, R.; Marucci, G.; Buccioni, M.; Dal Ben, D.; Lambertucci, C.; Lammi, C.; Mishra, R.C.; Thomas, A.; Cristalli, G. Evidence for the existence of a specific g protein-coupled receptor activated by guanosine. Chem. Med. Chem., 2011, 6(6), 1074-1080.
19. Haskó, G.; Sitkovsky, M.V.; Szabó, Cs. Immunomodulatory and neuroprotective effects of inosine. Trends Pharmacol. Sci., 2004, 25(3), 152-157.
20. Muto, J.; Lee, H.; Lee, H.; Uwaya, A.; Park, J.; Nakajima, S.; Nagata, K.; Ohno, M.; Ohsawa, I.; Mikami, T. Oral administration of inosine produces antidepressant-like effects in mice. Sci. Rep., 2014, 4:4199.
21. Skolnick, P.; Syapin, P.J.; Paugh, B.A.; Moncada, V.; Marangos, P.J.; Paul, S.M. Inosine, an endogenous ligand of the brain benzodiazepine receptor, antagonizes pentylenetetrazole-evoked seizures. Proc. Natl. Acad. Sci. U.S.A., 1979, 76(3), 1515-1518.
22. Ciccarelli, R.; Di Iorio, P.; D'Alimonte, I.; Giuliani, P.; Florio, T.; Caciagli, F.; Middlemiss, P.J.; Rathbone, M.P. Cultured astrocyte proliferation induced by extracellular guanosine involves endogenous adenosine and is raised by the co-presence of microglia. Glia, 2000, 29(3), 202-211.
23. Kovács, Z.; Dobolyi, Á.; Szikra, T.; Palkovits, M.; Juhász, G. Uneven regional distribution of nucleotide metabolism in human brain. Neurobiology (Bp), 1998, 6(3), 315-321.
24. Kovács, Z.; Kékesi, K.A.; Bobest, M.; Török, T.; Szilágyi, N.; Szikra, T.; Szepesi, Zs.; Nyilas, R.; Dobolyi, Á.; Palkovits, M.; Juhász, G. Post mortem degradation of nucleosides in the brain: comparison of human and rat brains for estimation of in vivo concentration of nucleosides. J. Neurosci. Methods, 2005, 148(1), 88-93.
25. Kékesi, K.A.; Kovács, Z.; Szilágyi, N.; Bobest, M.; Szikra, T.; Dobolyi, Á.; Juhász, G.; Palkovits, M. Concentration of nucleosides and related compounds in cerebral and cerebellar cortical areas and white matter of the human brain. Cell. Mol. Neurobiol., 2006, 26(4-6), 833-844.
26. Kovács, Z.; Dobolyi, Á.; Juhász, G.; Kékesi, A.K. Nucleoside map of the human central nervous system. Neurochem. Res., 2010, 35(3), 452-464.
27. Kovács, Z.; Juhász, G.; Dobolyi, Á.; Bobest, M.; Papp, V.; Takáts, L.; Kékesi, K.A. Gender- and age-dependent changes in nucleoside levels in the cerebral cortex and white matter of the human brain. Brain. Res. Bull., 2010, 81(6), 579-584.
28. Kovács, Z.; Dobolyi, A. Anatomical distribution of nucleoside system in the human brain and implications for therapy. In: Adenosine: a key link between metabolism and brain activity; Masino, S.A.; Boison, D., Eds.; Springer Science, Business Media: New York, 2013; pp. 621-656.
29. Kovács, Z.; Dobolyi, A.; Kékesi, K.A.; Juhász, G. 5'-nucleotidases, nucleosides and their distribution in the brain: pathological and therapeutic implications. Curr. Med. Chem., 2013, 20(34), 4217- 4240.
30. Kovács, Z.; Dobolyi, A. Functions and metabolism of brain nucleosides and their metabolites. Curr. Top. Med. Chem., 2011, 11(8), 907-908.
31. Burnstock, G. Physiology and pathophysiology of purinergic neurotransmission. Physiol. Rev., 2007, 87(2), 659-797.
32. Chiu, G.S.; Darmody, P.T.; Walsh, J.P.; Moon, M.L.; Kwakwa, K.A.; Bray, J.K.; McCusker, R.H.; Freund, G.G. Adenosine through the A2A adenosine receptor increases IL-1β in the brain contributing to anxiety. Brain Behav. Immun., 2014, 41, 218-231.
33. Dobolyi, A.; Juhász, G.; Kovács, Z.; Kardos, J. Uridine function in the central nervous system. Curr. Top. Med. Chem., 2011, 11(8), 1058-1067.
34. Schmidt, A.P.; Souza, D.O. The role of the guanine-based purinergic system in seizures and epilepsy. Open Neurosci. J., 2010, 4, 102-113.
35. Villar-Menéndez, I.; Porta, S.; Buira, S.P.; Pereira-Veiga, T.; Díaz- Sánchez, S.; Albasanz, J.L.; Ferrer, I.; Martín, M.; Barrachina, M. Increased striatal adenosine A2A receptor levels is an early event in Parkinson's disease-related pathology and it is potentially regulated by miR-34b. Neurobiol. Dis., 2014, 69C, 206-214.
36. Yamamoto, T.; Koyama, H.; Kurajoh, M.; Shoji, T.; Tsutsumi, Z.; Moriwaki, Y. Biochemistry of uridine in plasma. Clin. Chim. Acta., 2011, 412(19-20), 1712-1724.
37. Wurtman, R.J. A nutrient combination that can affect synapse formation. Nutrients, 2014, 6(4), 1701-1710.
38. De Oliveira, D.L.; Horn, J.F.; Rodrigues, J.M.; Frizzo, M.E.; Moriguchi, E.; Souza, D.O.; Wofchuk, S. Quinolinic acid promotes seizures and decreases glutamate uptake in young rats: reversal by orally administered guanosine. Brain Res., 2004, 1018(1), 48-54.
39. Kovacs, Z.; Kékesi, A.K.; Juhász, G.; Dobolyi, A. The antiepileptic potential of nucleosides. Curr. Med. Chem., 2014, 21(6), 788-821.
40. Lewin, E.; Bleck, V. Effect of inosine on seizures induced with pentylenetetrazole, bicuculline, or picrotoxin. Epilepsia, 1985, 26(3), 258-261.
41. Zhao, Q.; Shatskikh, T.; Marolewski, A.; Rusche, J.R.; Holmes, G.L. Effects of uridine on kindling. Epilepsy Behav., 2008, 13(1), 47-51.
42. Avoli, M.; Louvel, J.; Pumain, R.; Köhling, R. Cellular and molecular mechanisms of epilepsy in the human brain. Prog. Neurobiol., 2005, 77(3), 166-200.
43. Avoli, M. A brief history on the oscillating roles of thalamus and cortex in absence seizures. Epilepsia, 2012, 53(5), 779-789.
44. Avanzini, G.; Franceschetti, S. Cellular biology of epileptogenesis. Lancet Neurol., 2003, 2(1), 33-42.
45. Badawy, R.A.; Harvey, A.S.; Macdonell, R.A. Cortical hyperexcitability and epileptogenesis: understanding the mechanisms of epilepsy - part 1. J. Clin. Neurosci., 2009, 16(3), 355-365.
46. Pitkänen, A.; Lukasiuk, K. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol., 2011, 10(2), 173-186.
47. Pitkänen, A. Therapeutic approaches to epileptogenesis-hope on the horizon. Epilepsia, 2010, 51(Suppl 3), 2-17.
48. WHO. Fact sheet N 999 January, 2009; http://www.who.int/ mediacentre/factsheets/fs999/en/
49. Löscher, W.; Luna-Tortós, C.; Römermann, K.; Fedrowitz, M. Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected. Curr. Pharm. Des., 2011, 17(26), 2808-2828.
50. Perucca, P.; Gilliam, F.G. Adverse effects of antiepileptic drugs. Lancet Neurol., 2012, 11(9), 792-802.
51. Dragunow, M. Purinergic mechanisms in epilepsy. Open Neurosci. J., 2010, 4, 31-34.
52. Tomé, A.R.; Silva, H.; Cunha, R.A. Role of the purinergic neuromodulation system in epilepsy. Open Neurosci. J., 2010, 4, 64-83.
53. MacDonald, J.F.; Barker, J.L.; Paul, S.M.; Marangos, P.J.; Skolnick, P. Inosine may be an endogenous ligand for benzodiazepine receptors on cultured spinal neurons. Science, 1979, 205(4407), 715-717.
54. Héja, L. Astrocytic target mechanisms in epilepsy. Curr. Med. Chem., 2014, 21(6), 755-763.
55. Löscher, W.; Potschka, H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J. Pharmacol. Exp. Ther., 2002, 301(1), 7-14.
56. Ganzella, M.; Faraco, R.B.; Almeida, R.F.; Fernandes, V.F.; Souza, D.O. Intracerebroventricular administration of inosine is anticonvulsant against quinolinic acid-induced seizures in mice: an effect independent of benzodiazepine and adenosine receptors. Pharmacol. Biochem. Behav., 2011, 100(2), 271-274.
57. Lewin, E.; Bleck, V. Electroshock raises pentylenetetrazol threshold: possible role of inosine. Life Sci., 1983, 32(5), 433-436.
58. Lapin, I.P. Nicotinamide, inosine and hypoxanthine, putative endogenous ligands of the benzodiazepine receptor, opposite to diazepam are much more effective against kynurenine-induced seizures than against pentylenetetrazol-induced seizures. Pharmacol. Biochem. Behav., 1981, 14(5), 589-593.
59. Marangos, P.J.; Martino, A.M.; Paul, S.M.; Skolnick, P. The benzodiazepines and inosine antagonize caffeine-induced seizures. Psychopharmacology (Berl.), 1981, 72(3), 269-273.
60. Lara, D.R.; Schmidt, A.P.; Frizzo, M.E.; Burgos, J.S.; Ramírez, G.; Souza, D.O. Effect of orally administered guanosine on seizures and death induced by glutamatergic agents. Brain Res., 2001, 912(2), 176-180.
61. Schmidt, A.P.; Lara, D.R.; De Faria Maraschin, J.; Da Silveira Perla, A.; Souza, D.O. Guanosine and GMP prevent seizures induced by quinolinic acid in mice. Brain Res., 2000, 864(1), 40-43.
62. Schmidt, A.P.; Avila, T.T.; Souza, D.O. Intracerebroventricular guanine-based purines protect against seizures induced by quinolinic acid in mice. Neurochem. Res., 2005, 30(1), 69-73.
63. Torres, F.V.; da Silva Filho, M.; Antunes, C.; Kalinine, E.; Antoniolli, E.; Portela, L.V.; Souza, D.O.; Tort. A.B. Electrophysiological effects of guanosine and MK-801 in a quinolinic acid-induced seizure model. Exp. Neurol., 2010, 221(2), 296-306.
64. Vinadé, E.R.; Schmidt, A.P.; Frizzo, M.E.; Izquierdo, I.; Elisabetsky, E.; Souza, D.O. Chronically administered guanosine is anticonvulsant, amnesic and anxiolytic in mice. Brain Res., 2003, 977(1), 97-102.
65. Bonavita, V.; Piccoli, F.; Savettieri, G.; Zito, M. Observations on the therapeutic usefulness of uridine in epilepsy. Acta Neurol. (Napoli), 1975, 30(1), 30-34.
66. Connolly, G.P.; Duley, J.A. Uridine and its nucleotides: biological actions, therapeutic potentials. Trends Pharmacol. Sci., 1999, 20(5), 218-225.
67. Dwivedi, C.; Harbison, R.D. Anticonvulsant activities of delta-8 and delta-9 tetrahydrocannabinol and uridine. Toxicol. Appl. Pharmacol., 1975, 31(3), 452-458.
68. Guarneri, P.; Guarneri, R.; La Bella, V.; Piccoli, F. Interaction between uridine and GABA-mediated inhibitory transmission: studies in vivo and in vitro. Epilepsia, 1985, 26(6), 666-671.
69. Page, T.; Yu, A.; Fontanesi, J.; Nyhan, W.L. Developmental disorder associated with increased cellular nucleotidase activity. Proc. Natl. Acad. Sci. U.S.A., 1997, 94(21), 11601-11606.
70. Piccoli, F.; Camarda, R.; Bonavita, V. The brain nucleotide pattern of the rat after injection of uracil, uridine and uridine phosphate. Acta Neurol. (Napoli), 1971, 26(1), 109-117.
71. Roberts, C.A. Anticonvulsant effects of uridine: comparative analysis of metrazol and penicillin induced foci. Brain Res., 1973, 55(2), 291-308.
72. Roberts, C.A.; Kreisman, N.R.; Waltman, M. Uridine anticonvulsant effects: selective control of nucleoside incorporation in experimental epilepsy. Epilepsia, 1974, 15(4), 479-500.
73. Kovács, Z.; Slézia, A.; Bali, Z.K.; Kovács, P.; Dobolyi, A.; Szikra, T.; Hernádi, I.; Juhász, G. Uridine modulates neuronal activity and inhibits spike-wave discharges of absence epileptic Long Evans and Wistar Albino Glaxo/Rijswijk rats. Brain Res. Bull., 2013, 97, 16-23.
74. Zhao, Q.; Marolewski, A.; Rusche, J.R.; Holmes, G.L. Effects of uridine in models of epileptogenesis and seizures. Epilepsy Res., 2006, 70(1), 73-82.
75. Lewin, E.; Bleck, V. Electroshock seizures in mice: effect on brain adenosine and its metabolites. Epilepsia, 1981, 22(5), 577-581.
76. Oses, J.P.; Leke, R.; Portela, L.V.; Lara, D.R.; Schmidt, A.P.; Casali, E.A.; Wofchuk, S.; Souza, D.O.; Sarkis, J.J. Biochemical brain markers and purinergic parameters in rat CSF after seizure induced by pentylenetetrazol. Brain Res. Bull., 2004, 64(3), 237- 242.
77. Slézia, A.; Kékesi, A.K.; Szikra, T.; Papp, A.M.; Nagy, K.; Szente, M.; Maglóczky, Zs.; Freund, T.F.; Juhász, G. Uridine release during aminopyridine-induced epilepsy. Neurobiol. Dis., 2004, 16(3), 490-499.
78. Winn, H.R.; Welsh, J.E.; Rubio, R.; Berne, R.M. Changes in brain adenosine during bicuculline-induced seizures in rats. Effects of hypoxia and altered systemic blood pressure. Circ. Res., 1980, 47(4), 568-577.
79. McKernan, R.M.; Whiting, P.J. Which GABAA-receptor subtypes really occur in the brain? Trends Neurosci., 1996, 19(4), 139-143.
80. Asano, T.; Spector, S. Identification of inosine and hypoxanthine as endogenous ligands for the brain benzodiazepine-binding sites. Proc. Natl. Acad. Sci. U.S.A., 1979, 76(2), 977-981.
81. Marangos, P.J.; Trams, E.; Clark-Rosenberg, R.L.; Paul, S.M.; Skolnick, P. Anticonvulsant doses of inosine result in brain levels sufficient to inhibit [3H] diazepam binding. Psychopharmacology (Berl.), 1981, 75(2), 175-178.
82. Dunwiddie, T.V.; Masino, S.A. The role and regulation of adenosine in the central nervous system. Annu. Rev. Neurosci., 2001, 24, 31-55.
83. Klishin, A.; Lozovaya, N.; Krishtal, O. A1 adenosine receptors differentially regulate the N-methyl-D-aspartate and non-N-methyl- D-aspartate receptor-mediated components of hippocampal excitatory postsynaptic current in a Ca2+/Mg(2+)-dependent manner. Neuroscience, 1995, 65(4), 947-953.
84. Boison, D. The adenosine kinase hypothesis of epileptogenesis. Prog. Neurobiol., 2008, 84(3), 249-262.
85. Boison, D. Engineered adenosine-releasing cells for epilepsy therapy: human mesenchymal stem cells and human embryonic stem cells. Neurotherapeutics, 2009, 6(2), 278-283.
86. Van Gompel, J.J.; Bower, M.R.; Worrell, G.A.; Stead, M.; Chang, S.Y.; Goerss, S.J.; Kim, I.; Bennet, K.E.; Meyer, F.B.; Marsh, W.R.; Blaha, C.D.; Lee, K.H. Increased cortical extracellular adenosine correlates with seizure termination. Epilepsia, 2014, 55(2), 233-244.
87. Li, M.; Kang, R.; Shi, J.; Liu, G.; Zhang, J. Anticonvulsant activity of B2, an adenosine analog, on chemical convulsant-induced seizures. PLoS One, 2013, 8(6), e67060.
88. Sebastiao, A.M.; Ribeiro, J.A. Fine-tuning neuromodulation by adenosine. Trends Pharmacol. Sci., 2000, 21(9), 341-346.
89. Ciccarelli, R.; Di Iorio, P.; Ballerini, P.; Ambrosini, G.; Giuliani, P.; Tiboni, G.M.; Caciagli, F. Effects of exogenous ATP and related analogues on the proliferation rate of dissociated primary cultures of rat astrocytes. J. Neurosci. Res., 1994, 39(5), 556-566.
90. Huber, A.; Güttinger, M.; Möhler, H.; Boison, D. Seizure suppression by adenosine A(2A) receptor activation in a rat model of audiogenic brainstem epilepsy. Neurosci. Lett., 2002, 329(3), 289-292.
91. De Sarro, G.; De Sarro, A.; Di Paola, E.D.; Bertorelli, R. Effects of adenosine receptor agonists and antagonists on audiogenic seizuresensible DBA/2 mice. Eur. J. Pharmacol., 1999, 371(2-3), 137- 145.
92. Adami, M.; Bertorelli, R.; Ferri, N.; Foddi, M.C. Ongini, E. Effects of repeated administration of selective adenosine A1 and A2A receptor agonists on pentylenetetrazole-induced convulsions in the rat. Eur. J. Pharmacol., 1995, 294(2-3), 383-389.
93. Gomes, C.V.; Kaster, M.P.; Tomé, A.R.; Agostinho, P.M.; Cunha, R.A. Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Biochim. Biophys. Acta., 2011, 1808(5), 1380- 1399.
94. Sebastião, A.M.; Ribeiro, J.A. Tuning and fine-tuning of synapses with adenosine. Curr. Neuropharmacol., 2009, 7(3), 180-194.
95. Cunha, R.A. Neuroprotection by adenosine in the brain: from A1 receptor activation to A2A receptor blockade. Purinergic Signal., 2005, 1(2), 111-134.
96. Nishizaki, T.; Nagai, K.; Nomura, T.; Tada, H.; Kanno, T.; Tozaki, H.; Li, X.X.; Kondoh, T.; Kodama, N.; Takahashi, E.; Sakai, N.; Tanaka, K.; Saito, N. A new neuromodulatory pathway with a glial contribution mediated via A[2a] adenosine receptors. Glia, 2002, 39(2), 133-147.
97. Matos, M.; Augusto, E.; Dos Santos-Rodrigues, A.; Schwarzschild, M.A.; Chen, J.F.; Cunha, R.A.; Agostinho, P. Adenosine A2A receptors modulate glutamate uptake in cultured astrocytes and gliosomes. Glia, 2012, 60(5), 702-716.
98. Hosseinmardi, N.; Mirnajafi-Zadeh, J.; Fathollahi, Y.; Shahabi, P. The role of adenosine A1 and A2A receptors of entorhinal cortex on piriform cortex kindled seizures in rats. Pharmacol. Res., 2007, 56(2), 110-117.
99. Li, X.; Kang, H.; Liu, X.; Liu, Z.; Shu, K.; Chen, X.; Zhu, S. Effect of adenosine A2A receptor antagonist ZM241385 on amygdalakindled seizures and progression of amygdala kindling. J. Huazhong. Univ. Sci. Technolog. Med. Sci., 2012, 32(2), 257-264.
100. Zeraati, M.; Mirnajafi-Zadeh, J.; Fathollahi, Y.; Namvar, S.; Rezvani, M.E. Adenosine A1 and A2A receptors of hippocampal CA1 region have opposite effects on piriform cortex kindled seizures in rats. Seizure, 2006, 15(1), 41-48.
101. Shen, H.; Chen, G.J.; Harvey, B.K.; Bickford, P.C.; Wang, Y. Inosine reduces ischemic brain injury in rats. Stroke, 2005, 36(3), 654-659.
102. Bold, J.M.; Gardner, C.R.; Walker, R.J. Central effects of nicotinamide and inosine which are not mediated through benzodiazepine receptors. Br. J. Pharmacol., 1985, 84(3), 689-696.
103. Schultz, V.; Lowenstein, J.M. The purine nucleotide cycle. Studies of ammonia production and interconversions of adenine and hypoxanthine nucleotides and nucleosides by rat brain in situ. J. Biol. Chem., 1978, 253(6), 1938-1943.
104. Lewin, E.; Bleck, V. An adenosine deaminase inhibitor blocks the increase in pentylenetetrazol threshold produced by electroshock. Epilepsia, 1984, 25, 671-672.
105. Subrahmanyam, K.; Murthy, B.; Prasad, M.S.; Shrivastaw, K.P.; Sadasivudu, B. Adenosine deaminase in convulsions along with its regional, cellular and synaptosomal distribution in rat brain. Neurosci. Lett., 1984, 48(3), 327-331.
106. Etherington, L.A.; Frenguelli, B.G. Endogenous adenosine modulates epileptiform activity in rat hippocampus in a receptor subtype-dependent manner. Eur. J. Neurosci., 2004, 19(9), 2539- 2550.
107. Guarneri, P.; Guarneri, R.; Mocciaro, C.; Piccoli, F. Interaction of uridine with GABA binding sites in cerebellar membranes of the rat. Neurochem. Res., 1983, 8(12), 1537-1545.
108. Dobolyi, Á.; Szikra, T.; Kékesi, A.K.; Kovács, Z.; Juhász, G. Uridine is released by depolarization and inhibits unit activity in the rat hippocampus. Neuroreport, 1999, 10(14), 3049-3053.
109. Kardos, J.; Kovács, I.; Szárics, É.; Kovács, R.; Skuban, N.; Nyitrai, G.; Dobolyi, Á.; Juhász, G. Uridine activates fast transmembrane Ca2+ ion fluxes in rat brain homogenates. Neuroreport, 1999, 10(7), 1577-1582.
110. Liu, P.; Wu, C.; Song, W.; Yu, L.; Yang, X.; Xiang, R.; Wang, F.; Yang, J. Uridine decreases morphine-induced behavioral sensitization by decreasing dorsal striatal dopamine release possibly via agonistic effects At GABAA receptors. Eur. Neuropsychopharm., 2014, 24(9):1557-1566.
111. Cunha, R.A.; Ribeiro, J.A. Purinergic modulation of [(3)H]GABA release from rat hippocampal nerve terminals. Neuropharmacology, 2000, 39(7), 1156-1167.
112. Gonzalez, B.; Paz, F.; Florán, L.; Aceves, J.; Erlij, D.; Florán, B. Adenosine A2A receptor stimulation decreases GAT-1-mediated GABA uptake in the globus pallidus of the rat. Neuropharmacology, 2006, 51(1), 154-159.
113. Seifert, R.; Schultz, G. Involvement of pyrimidinoceptors in the regulation of cell functions by uridine and by uracil nucleotides. Trends Pharmacol. Sci., 1989, 10(9), 365-369.
114. Yamamoto, T.; Moriwaki, Y.; Cheng, J.; Takahashi, S.; Tsutsumi, Z.; Ka, T.; Hada, T. Effect of inosine on the plasma concentration of uridine and purine bases. Metabolism, 2002, 51(4), 438-442.
115. Porciúncula, L.O.; Vinadé, L.; Wofchuk, S.; Souza, D.O. Guanine based purines inhibit [(3)H]glutamate and [(3)H]AMPA binding at postsynaptic densities from cerebral cortex of rats. Brain Res., 2002, 928(1-2), 106-112.
116. Frizzo, M.E.; Schwalm, F.D.; Frizzo, J.K.; Soares, F.A.; Souza, D.O. Guanosine enhances glutamate transport capacity in brain cortical slices. Cell. Mol. Neurobiol., 2005, 25(5), 913-921.
117. Schmidt, A.P.; Tort, A.B.; Souza, D.O.; Lara, D.R. Guanosine and its modulatory effects on the glutamatergic system. Eur. Neuropsychopharmacol., 2008, 18(8), 620-622.
118. Tavares, R.G.; Schmidt, A.P.; Abud, J.; Tasca, C.I.; Souza, D.O. In vivo quinolinic acid increases synaptosomal glutamate release in rats: reversal by guanosine. Neurochem. Res., 2005, 30(4), 439- 444.
119. Tavares, R.G.; Schmidt, A.P.; Tasca, C.I.; Souza, D.O. Quinolinic acid-induced seizures stimulate glutamate uptake into synaptic vesicles from rat brain: effects prevented by guanine-based purines. Neurochem. Res., 2008, 33(1), 97-102.
120. Vinadé, E.R.; Schmidt, A.P.; Frizzo, M.E.; Portela, L.V.; Soares, F.A.; Schwalm, F.D.; Elisabetsky, E.; Izquierdo, I.; Souza, D.O. Effects of chronic administered guanosine on behavioral parameters and brain glutamate uptake in rats. J. Neurosci. Res., 2005, 79(1-2), 248-253.
121. Frizzo, M.E.; Antunes Soares, F.A.; Dall'Onder, L.P.; Lara, D.R.; Swanson, R.A.; Souza, D.O. Extracellular conversion of guaninebased purines to guanosine specifically enhances astrocyte glutamate uptake. Brain Res., 2003, 972(1-2), 84-89.
122. Frizzo, M.E.; Lara, D.R.; Dahm, K.C.; Prokopiuk, A.S.; Swanson, R.A.; Souza, D.O. Activation of glutamate uptake by guanosine in primary astrocyte cultures. Neuroreport, 2001, 12(4), 879-881.
123. Tasca, C.I.; Santos, T.G.; Tavares, R.G.; Battastini, A.M.; Rocha, J.B.; Souza, D.O. Guanine derivatives modulate L-glutamate uptake into rat brain synaptic vesicles. Neurochem. Int., 2004, 44(6), 423-431.
124. Di Iorio, P.; Ballerini, P.; Traversa, U.; Nicoletti, F.; D'Alimonte, I.; Kleywegt, S.; Werstiuk, E.S.; Rathbone, M.P.; Caciagli, F.; Ciccarelli, R. The antiapoptotic effect of guanosine is mediated by the activation of the PI 3-kinase/AKT/PKB pathway in cultured rat astrocytes. Glia, 2004, 46(4), 356-368.
125. Traversa, U.; Bombi, G.; Camaioni, E.; Macchiarulo, A.; Costantino, G.; Palmieri, C.; Caciagli, F.; Pellicciari, R. Rat brain guanosine binding site. Biological studies and pseudo-receptor construction. Bioorg. Med. Chem., 2003, 11(24), 5417-5425.
126. Soares, F.A.; Schmidt, A.P.; Farina, M.; Frizzo, M.E.S.; Tavares, R.G.; Portela, L.V.C.; Lara, D.R.; Souza, D.O. Anticonvulsant effect of GMP depends on its conversion to guanosine. Brain Res., 2004, 1005(1-2), 182-186.
127. Schmidt, A.P.; Böhmer, A.E.; Schallenberger, C.; Antunes, C.; Tavares, R.G.; Wofchuk, S.T.; Elisabetsky, E.; Souza, D.O. Mechanisms involved in the antinociception induced by systemic administration of guanosine in mice. Br. J. Pharmacol., 2010, 159(6), 1247-1263.
128. Yamamoto, I.; Kimura, T.; Tateoka, Y.; Watanabe, K.; Ho, I.K. N3-benzyluridine exerts hypnotic activity in mice. Chem. Pharm. Bull. (Tokyo), 1985, 33(9), 4088-4090.
129. Yamamoto, I.; Kimura, T.; Tateoka, Y.; Watanabe, K.; Ho, I.K. Nsubstituted oxopyrimidines and nucleosides: structure-activity relationship for hypnotic activity as central nervous system depressant. J. Med. Chem., 1987, 30(12), 2227-2231.
130. Yamamoto, I.; Kuze, J.; Kimura, T.; Watanabe, K.; Kondo, S.; Ho, I.K. The potent depressant effects of N3-phenacyluridine in mice. Biol. Pharm. Bull., 1994, 17(4), 514-516.
131. Kimura, T.; Watanabe, K.; Koshigami, M.; Miyamoto, K.; Kondo, S.; Yamamoto, I. The 6-azauridine analogues possessing sedative and hypnotic effects. Nucleic Acids Symp. Ser., 1992, 27, 199-200.
132. Koshigami, M.; Watanabe, K.; Kimura, T.; Yamamoto, I. Central depressant effects of N3-substituted 6-azauridines in mice. Chem. Pharm. Bull. (Tokyo), 1991, 39(10), 2597-2599.
133. Mabley, J.G.; Pacher, P.; Murthy, K.G.; Williams, W.; Southan, G.J.; Salzman, A.L.; Szabo, C. The novel inosine analogue INO- 2002 exerts an anti-inflammatory effect in a murine model of acute lung injury. Shock, 2009, 32(3), 258-262.
134. Xu, L.; Chong, Y.; Hwang, I.; D'Onofrio, A.; Amore, K.; Beardsley, G.P.; Li, C.; Olson, A.J.; Boger, D.L.; Wilson, I.A. Structure-based design, synthesis, evaluation, and crystal structures of transition state analogue inhibitors of inosine monophosphate cyclohydrolase. J. Biol. Chem., 2007, 282(17), 13033-13046.
135. Liekens, S.; Hernández, A.I.; Ribatti, D.; De Clercq, E.; Camarasa, M.J.; Pérez-Pérez, M.J.; Balzarini, J. The nucleoside derivative 5'- O-trityl-inosine (KIN59) suppresses thymidine phosphorylasetriggered angiogenesis via a noncompetitive mechanism of action. J. Biol. Chem., 2004, 279(28), 29598-29605.
136. De Clercq, E.; Andrei, G.; Snoeck, R.; De Bolle, L.; Naesens, L.; Degrève, B.; Balzarini, J.; Zhang, Y.; Schols, D.; Leyssen, P.; Ying, C.; Neyts, J. Acyclic/carbocyclic guanosine analogues as anti-herpesvirus agents. Nucleosides Nucleotides Nucleic Acids, 2001, 20(4-7), 271-285.
137. Ali-von Laue, C.; Zoschke, C.; Do, N.; Lehnen, D.; Küchler, S.; Mehnert, W.; Blaschke, T.; Kramer, K.D.; Plendl, J.; Weindl, G.; Korting, H.C.; Hoeller Obrigkeit, D.; Merk, H.F.; Schäfer-Korting, M. Improving topical non-melanoma skin cancer treatment: In vitro efficacy of a novel guanosine-analog phosphonate. Skin Pharmacol. Physiol., 2014, 27(4), 173.
138. Boison, D. Adenosine augmentation therapies (AATs) for epilepsy: prospect of cell and gene therapies. Epilepsy Res., 2009, 85(2-3), 131-141.
139. Pastor-Anglada, M.; Casado, F.J.; Valdés, R.; Mata, J.; García- Manteiga, J.; Molina, M. Complex regulation of nucleoside transporter expression in epithelial and immune system cells. Mol. Membr. Biol., 2001, 18(1), 81-85.
140. Dunwiddie, T.V.; Worth, T. Sedative and anticonvulsant effects of adenosine analogs in mouse and rat. J. Pharmacol. Exp. Ther., 1982, 220(1), 70-76.
141. Malhotra, J.; Gupta, Y.K. Effect of adenosine receptor modulation on pentylenetetrazole-induced seizures in rats. Br. J. Pharmacol., 1997, 120(2), 282-288.
142. Shryock, J.C.; Belardinelli, L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am. J. Cardiol., 1997, 79(12A), 2-10.
143. Chen, P.; Goldberg, D.E.; Kolb, B.; Lanser, M.; Benowitz, L.I. Inosine induces axonal rewiring and improves behavioral outcome after stroke. Proc. Natl. Acad. Sci. USA, 2002, 99(13), 9031-9036.